NDC product
Xultophy 100/3.6
NDC 0169-2911 · Novo Nordisk
Key facts
| Product NDC | 0169-2911 |
|---|---|
| Proprietary name | Xultophy 100/3.6 |
| Nonproprietary name | insulin degludec and liraglutide |
| Substances | INSULIN DEGLUDEC, LIRAGLUTIDE |
| Dosage form | INJECTION, SOLUTION |
| Route | SUBCUTANEOUS |
| Labeler | Novo Nordisk |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | BLA |
| Application number | BLA208583 |
| Pharmacologic classes | GLP-1 Receptor Agonist [EPC], Glucagon-Like Peptide 1 [CS], Glucagon-like Peptide-1 (GLP-1) Agonists [MoA], Insulin Analog [EPC], Insulin [CS] |
| Marketing start | Nov 21, 2016 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: